LY 3113593

Drug Profile

LY 3113593

Alternative Names: LY3113593

Latest Information Update: 09 Feb 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Eli Lilly
  • Class
  • Mechanism of Action Bone morphogenetic protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Anaemia

Most Recent Events

  • 22 Jun 2016 Eli Lilly completes a phase I trial for Anaemia (In patients with chronic kidney disease) in USA (IV) (NCT02604160)
  • 25 Jan 2016 Phase-II clinical trials in Anaemia in USA (Parenteral) before January 2016
  • 01 Aug 2015 Eli Lilly completes a phase I trial in Anaemia in USA (NCT02144285)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top